Eleven Biotherapeutics (EBIO) & Its Rivals Head-To-Head Comparison
Eleven Biotherapeutics (NASDAQ: EBIO) is one of 294 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Eleven Biotherapeutics to related businesses based on the strength of its profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Volatility and Risk
Eleven Biotherapeutics has a beta of 3.51, meaning that its share price is 251% more volatile than the S&P 500. Comparatively, Eleven Biotherapeutics’ rivals have a beta of 6.61, meaning that their average share price is 561% more volatile than the S&P 500.
Valuation & Earnings
This table compares Eleven Biotherapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Eleven Biotherapeutics||$29.90 million||$9.65 million||7.14|
|Eleven Biotherapeutics Competitors||$473.33 million||$171.79 million||-7.10|
Eleven Biotherapeutics’ rivals have higher revenue and earnings than Eleven Biotherapeutics. Eleven Biotherapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Eleven Biotherapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eleven Biotherapeutics Competitors||-5,540.84%||-391.69%||-42.50%|
Insider and Institutional Ownership
5.1% of Eleven Biotherapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 28.7% of Eleven Biotherapeutics shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of current recommendations for Eleven Biotherapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eleven Biotherapeutics Competitors||727||3165||11792||265||2.73|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.49%. Given Eleven Biotherapeutics’ rivals higher possible upside, analysts plainly believe Eleven Biotherapeutics has less favorable growth aspects than its rivals.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).
Receive News & Stock Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.